Literature DB >> 17448922

Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant.

David M Weinstock1, Mary Conlon, Christine Iovino, Tanya Aubrey, Carlota Gudiol, Elyn Riedel, James W Young, Timothy E Kiehn, Gianna Zuccotti.   

Abstract

Bloodstream infection caused by vancomycin-resistant enterococcus (VRE) is associated with very high mortality among allogeneic hematopoietic stem cell transplant (alloHSCT) recipients. However, it remains unclear whether VRE bloodstream infection directly causes mortality in the early posttransplant period or is simply a marker of poor outcome. To determine the risk factors for VRE bloodstream infection and its effect on outcome, we followed 92 patients screened for stool colonization by VRE upon admission for alloHSCT. Patient records were reviewed to determine outcomes, including mortality and microbiologic failure. Colonization by VRE was extremely common, occurring in 40.2% of patients. VRE bloodstream infection developed in 34.2% of colonized patients by day +35, compared to 1.8% without VRE colonization (P < .01). VRE bloodstream infection was associated with a significant decrement in survival and frequent microbiologic failure, despite treatment with linezolid and/or daptomycin. Five (35.7%) of 14 patients with VRE bloodstream infection had attributable mortality or contributing mortality from the infection. Strain typing by pulsed-field gel electrophoresis identified 9 different VRE strains among the 37 colonized patients and 5 patients with different strains recovered from the stool and the blood. In conclusion, stool screening effectively identified patients at extremely high risk for VRE bloodstream infection. The high mortality of VRE in the early posttransplant period supports the use of empiric antibiotics with activity against VRE during periods of fever and neutropenia in colonized patients.

Entities:  

Mesh:

Year:  2007        PMID: 17448922     DOI: 10.1016/j.bbmt.2007.01.078

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  64 in total

1.  Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies.

Authors:  B J Liss; J J Vehreschild; O A Cornely; M Hallek; G Fätkenheuer; H Wisplinghoff; H Seifert; M J G T Vehreschild
Journal:  Infection       Date:  2012-06-05       Impact factor: 3.553

2.  Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans.

Authors:  Carles Ubeda; Ying Taur; Robert R Jenq; Michele J Equinda; Tammy Son; Miriam Samstein; Agnes Viale; Nicholas D Socci; Marcel R M van den Brink; Mini Kamboj; Eric G Pamer
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

3.  TLR-7 activation enhances IL-22-mediated colonization resistance against vancomycin-resistant enterococcus.

Authors:  Michael C Abt; Charlie G Buffie; Bože Sušac; Simone Becattini; Rebecca A Carter; Ingrid Leiner; James W Keith; David Artis; Lisa C Osborne; Eric G Pamer
Journal:  Sci Transl Med       Date:  2016-02-24       Impact factor: 17.956

4.  Pretransplant Gut Colonization with Intrinsically Vancomycin-Resistant Enterococci (E. gallinarum and E. casseliflavus) and Outcomes of Allogeneic Hematopoietic Cell Transplantation.

Authors:  Armin Rashidi; Maryam Ebadi; Robin R Shields-Cutler; Todd E DeFor; Gabriel A Al-Ghalith; Patricia Ferrieri; Jo-Anne H Young; Gary M Dunny; Dan Knights; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2018-01-31       Impact factor: 5.742

5.  European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia.

Authors:  Diana Averbuch; Christina Orasch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

6.  Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors:  Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

7.  Prior colonization is associated with increased risk of antibiotic-resistant Gram-negative bacteremia in cancer patients.

Authors:  Aaron S Hess; Michael Kleinberg; John D Sorkin; Giora Netzer; Jennifer K Johnson; Michelle Shardell; Kerri A Thom; Anthony D Harris; Mary-Claire Roghmann
Journal:  Diagn Microbiol Infect Dis       Date:  2014-01-30       Impact factor: 2.803

8.  Bloodstream Infection Due to Vancomycin-resistant Enterococcus Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study.

Authors:  Genovefa A Papanicolaou; Celalettin Ustun; Jo-Anne H Young; Min Chen; Soyoung Kim; Kwang Woo Ahn; Krishna Komanduri; Caroline Lindemans; Jeffery J Auletta; Marcie L Riches
Journal:  Clin Infect Dis       Date:  2019-10-30       Impact factor: 9.079

9.  The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients.

Authors:  Michael J Satlin; Rosemary Soave; Alexandra C Racanelli; Tsiporah B Shore; Koen van Besien; Stephen G Jenkins; Thomas J Walsh
Journal:  Leuk Lymphoma       Date:  2014-03-24

10.  Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy.

Authors:  Graeme N Forrest; Mary-Claire Roghmann; Latoya S Toombs; Jennifer K Johnson; Elizabeth Weekes; Durry P Lincalis; Richard A Venezia
Journal:  Antimicrob Agents Chemother       Date:  2008-07-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.